Nkarta (NKTX) Non Operating Investment Income (2022 - 2026)
Nkarta's quarterly Non Operating Investment Income came in at -$537000.0 in Q1 2026, down 2340.91% year-on-year from $23963.5 in Q1 2025, and down 316.28% quarter-over-quarter from -$129000.0 in Q4 2025.
Nkarta has reported Non Operating Investment Income for 5 years, with the latest figure at -$537000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income fell 2340.91% year-over-year to -$537000.0; the trailing twelve-month figure through Mar 2026 stood at -$782000.0 (down 200.39% YoY), and the FY2025 full-year result was -$267000.0, down 140.09% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$537000.0, down from -$129000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $2.0 million in Q3 2024, with the low at -$1.0 million in Q4 2024.
- Average Non Operating Investment Income over 5 years is $1176.5, with a median of -$135000.0 recorded in 2024.
- Year-over-year, Non Operating Investment Income soared 929.69% in 2024 and sank 2340.91% in 2026.
- Tracing NKTX's Non Operating Investment Income over 5 years: stood at $642000.0 in 2022, then tumbled by 35.05% to $417000.0 in 2023, then sank by 349.4% to -$1.0 million in 2024, then surged by 87.6% to -$129000.0 in 2025, then plunged by 316.28% to -$537000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$537000.0 (Q1 2026), -$129000.0 (Q4 2025), and $174000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -537,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -537,000.00 |
| Mar 31, 2026 | -537,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2024 | -1.04 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | -136,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -135,000.00 |
| Mar 31, 2024 | -135,000.00 |
| Dec 31, 2023 | 417,000.00 |
| Dec 31, 2023 | 417,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | -427,000.00 |
| Jun 30, 2023 | -427,000.00 |
| Mar 31, 2023 | 505,000.00 |
| Mar 31, 2023 | 505,000.00 |
| Dec 31, 2022 | 642,000.00 |
| Dec 31, 2022 | 642,000.00 |
| Sep 30, 2022 | -390,000.00 |
| Sep 30, 2022 | -390,000.00 |
| Jun 30, 2022 | -325,000.00 |
| Jun 30, 2022 | -325,000.00 |
| Mar 31, 2022 | -456,000.00 |
| Mar 31, 2022 | -456,000.00 |